MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$8,594K
Free Cash flow
-$22,702K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Proceeds from issuance of common...
Prepaid expenses and other asset...
Others
Negative Cash Flow Breakdown
Purchase of available-for-sale s...
Net loss
Payment of issuance costs associ...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-23,331
-22,136
-24,788
-44,587
Depreciation expense
20
19
19
17
Stock-based compensation expense
3,666
3,177
1,664
1,479
Accretion of debt discount on available-for-sale securities
1,041
7
-9
6
Prepaid expenses and other assets
-1,697
3,197
2,166
1,998
Accounts payable
388
3,095
4,497
558
Accrued liabilities
-4,285
-198
3,262
3,632
Income taxes payable
-
-
1,037
-
Other liabilities
184
439
-
-
Net cash used in operating activities
-22,702
-18,808
-16,466
-14,000
Purchase of available-for-sale securities
147,841
-
0
-
Purchase of property and equipment
0
0
0
55
Proceeds from redemptions of short-term investments
0
0
0
0
Net cash (used in) provided by investing activities
-147,841
0
0
-55
Proceeds from issuance of common stock
150,000
-
0
1,779
Proceeds from issuance of common stock and pre-funded warrants
0
-
0
0
Proceeds from issuance of common stock upon exercise of underwriters' option
22,500
-
-
-
Payment of issuance costs associated with financings
10,565
0
0
475
Proceeds from issuance of common stock under espp
0
101
0
9
Proceeds from exercise of warrants and options
25
-
15
19
Taxes paid related to net share settlement of equity awards
11
27
6
5
Settlement of fractional shares paid in cash
-
-
0
0
Net cash provided by financing activities
161,949
74
9
1,325
Net (decrease) increase in cash and cash equivalents
-8,594
-18,734
-16,457
-12,730
Cash and cash equivalents beginning of period
58,223
76,957
93,414
22,244
Cash and cash equivalents end of period
49,629
58,223
76,957
93,414
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock
$150,000K
Proceeds from issuance of
common stock upon...
$22,500K
Proceeds from exercise of
warrants and options
$25K
Net cash provided by
financing activities
$161,949K
(138.07%↑ Y/Y)
Canceled cashflow
$10,576K
Net (decrease)
increase in cash and cash...
-$8,594K
(-110.24%↓ Y/Y)
Canceled cashflow
$161,949K
Stock-based compensation
expense
$3,666K
(17.69%↑ Y/Y)
Prepaid expenses and
other assets
-$1,697K
(-6.73%↓ Y/Y)
Accounts payable
$388K
(-20.49%↓ Y/Y)
Other liabilities
$184K
Depreciation expense
$20K
(-28.57%↓ Y/Y)
Payment of issuance
costs associated with...
$10,565K
(51.67%↑ Y/Y)
Taxes paid related to
net share...
$11K
(-38.89%↓ Y/Y)
Net cash (used in)
provided by investing...
-$147,841K
(-507.40%↓ Y/Y)
Net cash used in
operating activities
-$22,702K
(-11.20%↓ Y/Y)
Canceled cashflow
$5,955K
Purchase of
available-for-sale securities
$147,841K
Net loss
-$23,331K
(13.28%↑ Y/Y)
Accrued liabilities
-$4,285K
(-384.15%↓ Y/Y)
Accretion of debt discount
on...
$1,041K
(333.75%↑ Y/Y)
Buy us a coffee
Forte Biosciences, Inc. (FBRX)
Forte Biosciences, Inc. (FBRX)